Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferinject high- and low-dose regimens versus oral iron in iron deficiency anaemia with non-dialysis-dependent chronic kidney disease
2009-015579-28Phase 3Completed
- Sponsor
- Vifor Pharma
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose and ferrous sulfate in iron deficiency anemia (IDA) (3 arms), sponsored by Vifor Pharma. Primary endpoint: Time to initiation of other anaemia management. Started Oct 2009; status: completed.
02
Drugs
ferric carboxymaltoseferrous sulfate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2009-015579-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015579-28.